BEHIND BOTANICAL DRUGS

THE EXPERTISE YOU CAN TRUST

NatureCeuticals pioneering - Botanical drug for cancer by targeting a key physiological process known as angiogenesis which plays crucial role in all tumor growth and development.

NatureCeuticals is a pharmaceutical company that specialises in prescription base botanical drugs.


FEATURED NEWS

LEADING BOTANICAL PHARMACEUTICAL COMPANY

PIC/S and GMP Base
Manufacturing
Facility





HALAL Certified
Botanical Drugs







Pesticide and Herbicide
Free Botanical Drugs










TGA, USFDA & NPRA
Approved Botanical
Drugs








About Us

NatureCeuticals is established based on research collaboration between top Australian and Malaysian universities. We aspire to transform medicinal herbs into main stream pharmaceuticals that are safe and effective. We go to great lengths to achieve what is thought to be impossible for herbs by introducing ground breaking technologies that helps to catapult herbs into pharmaceuticals.

Our Technologies

Our proprietary state-of-the-art manufacturing and formulation technologies help to improve the potency of our herbal products. These help to increase the amount of vital plant nutrients and enhance their absorption making our herbal products far more effective than their natural form.

Research

We conduct clinical and preclinical studies on our products to validate their safety and effectiveness. Our commitment to continuously improve herbal pharmaceuticals has led us to establish our very own not-for-profit research institute to advance our scientific endeavour . We also support various university research projects to help to deepen our knowledge and understanding in modern herbal medicine.


NATURECEUTICALS FEATURED NEWS




RECENT NEWS


Dec 2019

Phase 2 clinical studies on breast cancer patients is currently ongoing on Nuvastatic. This study is expected to be completed before end of 2020.


Continue reading »

Oct 2019

Nuvastatic has obtained approval by Malaysian Drug regulatory authority as complementary medicine.


Continue reading »

Aug 2019

Nuvastatic has obtained Approval for Phase 1b/2a for Diabetic Retinopathy. Currently more than 100 patients are being recruited for this study.


Continue reading »

Jun 2019

Nuvastatic has obtained approval to commence phase 2 clinical study for colon cancer. This study is currently underway and expected to be completed by 3rd quarter 2020.


Continue reading »


IN THIS SECTION

Interested? please learn
more and buy now.

Order now

want tools,tips and
product support?

Sign Up
Facebook Email